Similarly, Zhu et al demonstrated the safety and feasibility of intravenously administered CD34+, CD133+, and KDR+ EPCs into children with idiopathic pulmonary arterial hypertension (IPAH). This evidence concerns the gene PROM1 and idiopathic pulmonary arterial hypertension.